Lung cancer committee

R. Byhardt; R. Komaki; D. Ettinger; D. Johnstone; J. Bradley; A. Franko; L. Gaspar; M. Gillin; C. Langer; E. Layne; B. Movsas; R. Munden; W. Sause; J. Stern; J. Hsu; W. Hartsell; R. Yesner

doi:10.1016/S0360-3016(01)01779-5

Lung cancer committee

R. Byhardt, R. Komaki, D. Ettinger, D. Johnstone, J. Bradley, A. Franko, L. Gaspar, M. Gillin, C. Langer, E. Layne, B. Movsas, R. Munden, W. Sause, J. Stern, J. Hsu, W. Hartsell, R. Yesner

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	44-52
Number of pages	9
Journal	International Journal of Radiation Oncology Biology Physics
Volume	51
Issue number	3 SUPPL. 2
DOIs	https://doi.org/10.1016/S0360-3016(01)01779-5
State	Published - 2001

Access to Document

10.1016/S0360-3016(01)01779-5

Cite this

@article{0e38a5b5dc704492a61f91458b3ecbee,

title = "Lung cancer committee",

author = "R. Byhardt and R. Komaki and D. Ettinger and D. Johnstone and J. Bradley and A. Franko and L. Gaspar and M. Gillin and C. Langer and E. Layne and B. Movsas and R. Munden and W. Sause and J. Stern and J. Hsu and W. Hartsell and R. Yesner",

note = "Funding Information: In addition to the potential for enhanced tumor control, new adjuvants with unique biologic targets, such as AIs and STMs, may also be less toxic than cytotoxic chemotherapy. Aberrations in key signal transduction pathways provide a growth-advantaged environment for tumor cells. Inhibiting these pathways causes growth arrest, and significant synergy exists with RT. Thus, a future randomized Phase II study could combine either RT, gemcitabine, and carboplatin or RT, gemcitabine, and paclitaxel from L0017 with a promising AI in each arm or with an AI in one arm and an STM in the other arm. As newer and more specific AIs and STMs become available, RTOG will evaluate them. Laboratory projects, funded by an RTOG seed grant and/or National Cancer Institute R01 mechanisms, will identify appropriate molecular targets and agents for future study. If new hypoxic cytotoxics, like tirapazamine, appear promising, they may also be tested. ",

year = "2001",

doi = "10.1016/S0360-3016(01)01779-5",

language = "English",

volume = "51",

pages = "44--52",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

number = "3 SUPPL. 2",

}

TY - JOUR

T1 - Lung cancer committee

AU - Byhardt, R.

AU - Komaki, R.

AU - Ettinger, D.

AU - Johnstone, D.

AU - Bradley, J.

AU - Franko, A.

AU - Gaspar, L.

AU - Gillin, M.

AU - Langer, C.

AU - Layne, E.

AU - Movsas, B.

AU - Munden, R.

AU - Sause, W.

AU - Stern, J.

AU - Hsu, J.

AU - Hartsell, W.

AU - Yesner, R.

N1 - Funding Information: In addition to the potential for enhanced tumor control, new adjuvants with unique biologic targets, such as AIs and STMs, may also be less toxic than cytotoxic chemotherapy. Aberrations in key signal transduction pathways provide a growth-advantaged environment for tumor cells. Inhibiting these pathways causes growth arrest, and significant synergy exists with RT. Thus, a future randomized Phase II study could combine either RT, gemcitabine, and carboplatin or RT, gemcitabine, and paclitaxel from L0017 with a promising AI in each arm or with an AI in one arm and an STM in the other arm. As newer and more specific AIs and STMs become available, RTOG will evaluate them. Laboratory projects, funded by an RTOG seed grant and/or National Cancer Institute R01 mechanisms, will identify appropriate molecular targets and agents for future study. If new hypoxic cytotoxics, like tirapazamine, appear promising, they may also be tested.

PY - 2001

Y1 - 2001

UR - http://www.scopus.com/inward/record.url?scp=85047686552&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(01)01779-5

DO - 10.1016/S0360-3016(01)01779-5

M3 - Article

C2 - 11641014

AN - SCOPUS:85047686552

SN - 0360-3016

VL - 51

SP - 44

EP - 52

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 3 SUPPL. 2

ER -

Lung cancer committee

Access to Document

Other files and links

Cite this